WNY Asset Management LLC Acquires 272 Shares of Bristol Myers Squibb Company $BMY

WNY Asset Management LLC raised its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 4.4% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 6,395 shares of the biopharmaceutical company’s stock after purchasing an additional 272 shares during the period. WNY Asset Management LLC’s holdings in Bristol Myers Squibb were worth $296,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Quaker Wealth Management LLC increased its stake in shares of Bristol Myers Squibb by 180.4% during the second quarter. Quaker Wealth Management LLC now owns 1,914 shares of the biopharmaceutical company’s stock valued at $89,000 after purchasing an additional 4,296 shares in the last quarter. Oarsman Capital Inc. increased its position in shares of Bristol Myers Squibb by 11.3% during the second quarter. Oarsman Capital Inc. now owns 39,683 shares of the biopharmaceutical company’s stock valued at $1,837,000 after acquiring an additional 4,043 shares in the last quarter. New York Life Investment Management LLC increased its position in shares of Bristol Myers Squibb by 1.4% during the second quarter. New York Life Investment Management LLC now owns 315,242 shares of the biopharmaceutical company’s stock valued at $14,593,000 after acquiring an additional 4,450 shares in the last quarter. Howard Capital Management Inc. increased its position in shares of Bristol Myers Squibb by 24.6% during the second quarter. Howard Capital Management Inc. now owns 23,215 shares of the biopharmaceutical company’s stock valued at $1,075,000 after acquiring an additional 4,585 shares in the last quarter. Finally, Wincap Financial LLC increased its position in shares of Bristol Myers Squibb by 11.7% during the second quarter. Wincap Financial LLC now owns 19,382 shares of the biopharmaceutical company’s stock valued at $897,000 after acquiring an additional 2,026 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Price Performance

Shares of Bristol Myers Squibb stock opened at $42.62 on Thursday. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $63.33. The stock’s fifty day moving average is $45.43 and its 200 day moving average is $46.87. The stock has a market cap of $86.74 billion, a P/E ratio of 17.18, a P/E/G ratio of 2.24 and a beta of 0.33. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, topping analysts’ consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The company had revenue of $12.27 billion for the quarter, compared to analysts’ expectations of $11.32 billion. During the same period last year, the firm earned $2.07 EPS. Bristol Myers Squibb’s revenue for the quarter was up .6% compared to the same quarter last year. Sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Friday, October 3rd will be paid a dividend of $0.62 per share. The ex-dividend date is Friday, October 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.8%. Bristol Myers Squibb’s payout ratio is 100.00%.

Insider Buying and Selling at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 56,000 shares of Bristol Myers Squibb stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the transaction, the executive vice president owned 167,379 shares in the company, valued at approximately $7,922,048.07. The trade was a 25.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.09% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Daiwa Capital Markets downgraded shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price target for the company. in a research report on Tuesday, August 5th. Citigroup reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a research report on Monday, October 13th. Morgan Stanley reaffirmed a “hold” rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Dbs Bank raised shares of Bristol Myers Squibb to a “moderate buy” rating in a research report on Thursday, October 2nd. Finally, Daiwa America downgraded shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and fourteen have given a Hold rating to the company. Based on data from MarketBeat, Bristol Myers Squibb presently has a consensus rating of “Hold” and a consensus target price of $57.23.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.